NCT03596372: Study of BAY1834942 in Patients With Solid Tumors

NCT03596372
Breast Cancer Type: HER2+, HR+ & HER2-negative, Triple Negative
Hormone Mutations: ER++, PR+
Other Mutations: CEACAM
Breast Cancer Tissue: 
Recruitment Status: Recruiting
Ph+ase 1
Drug Category: Immunotherapy, Therapeutic Antibody, Chemotherapy

Key Eligibility Criteria:

Gender: All
Age: 18 Years and older (Adult, Older Adult)
Location of Metastases: 
Additional Notes: Breast cancer patients are not eligible for the expansion phase
Exclusions: Patients with active symptomatic or untreated brain metastases- see trial for details
https://ClinicalTrials.gov/show/NCT03596372

Comments are closed.

Up ↑